These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Nesto RW Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of dyslipidemia: how and when to combine lipid lowering drugs]. Schulz I Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):344-59. PubMed ID: 16767301 [TBL] [Abstract][Full Text] [Related]
11. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. Isles CG; Paterson JR QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551 [TBL] [Abstract][Full Text] [Related]
12. Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid. Schachter M Cardiovasc Drugs Ther; 2005 Dec; 19(6):415-22. PubMed ID: 16453091 [TBL] [Abstract][Full Text] [Related]
14. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. Chapman MJ Cardiovasc Drugs Ther; 2005 Mar; 19(2):135-9. PubMed ID: 16025232 [TBL] [Abstract][Full Text] [Related]
15. Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials. Taylor AJ Am J Cardiol; 2008 Apr; 101(8A):36B-43B. PubMed ID: 18375240 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. Knopp RH; Paramsothy P; Atkinson B; Dowdy A Am J Cardiol; 2008 Apr; 101(8A):48B-57B. PubMed ID: 18375242 [TBL] [Abstract][Full Text] [Related]
18. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease. Borgia MC; Medici F Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525 [TBL] [Abstract][Full Text] [Related]
19. Dyslipidemia and cardiovascular risk: the importance of early prevention. Miller M QJM; 2009 Sep; 102(9):657-67. PubMed ID: 19498039 [TBL] [Abstract][Full Text] [Related]
20. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future? Kastelein JJ Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]